5
Participants
Start Date
May 1, 2017
Primary Completion Date
March 31, 2023
Study Completion Date
March 31, 2023
Mature dendritic cell (DC) vaccine
Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
Cyclophosphamide 300mg/m^2
administered prior to subject's first DC dose
Pembrolizumab
administered 7-8 weeks after subject's last DC dose
University of Pennsylvania, Philadelphia
University of Pennsylvania
OTHER